DDInter204 DDInter927
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
Bicalutamide {u} (Compound) binds {v} (Gene) AR
Bicalutamide {u} (Compound) upregulates {v} (Gene) USP6NL
Bicalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Bicalutamide {u} (Compound) downregulates {v} (Gene) TUBB6
Bicalutamide {u} (Compound) causes {v} (Side Effect) Melaena
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Bicalutamide (Compound) resembles Enzalutamide (Compound)
Bicalutamide (Compound) treats prostate cancer (Disease)
Bicalutamide (Compound) binds AR (Gene)
Bicalutamide (Compound) upregulates USP6NL (Gene)
Bicalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Bicalutamide (Compound) downregulates TUBB6 (Gene)
Bicalutamide (Compound) causes Melaena (Side Effect)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine